Here we report the results of the phase 1 trials evaluating the safety and tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of the high affinity anti-tau monoclonal antibody JNJ-63733657 in healthy participants (non-Japanese and Japanese) and participants with prodromal or mild AD. The gene discussed is MAPT; the disease is Alzheimer disease.